Your browser is no longer supported. Please, upgrade your browser.
Settings
TROV TrovaGene, Inc. daily Stock Chart
TROV [NASD]
TrovaGene, Inc.
Index- P/E- EPS (ttm)-1.03 Insider Own0.30% Shs Outstand30.91M Perf Week-6.80%
Market Cap161.04M Forward P/E- EPS next Y-1.11 Insider Trans0.00% Shs Float25.59M Perf Month1.56%
Income-30.60M PEG- EPS next Q-0.33 Inst Own31.10% Short Float14.69% Perf Quarter-1.51%
Sales0.40M P/S402.60 EPS this Y-38.30% Inst Trans-8.16% Short Ratio11.21 Perf Half Y1.17%
Book/sh1.09 P/B4.78 EPS next Y16.50% ROA-45.10% Target Price6.75 Perf Year-5.10%
Cash/sh1.64 P/C3.18 EPS next 5Y- ROE-69.10% 52W Range2.85 - 7.58 Perf YTD-3.52%
Dividend- P/FCF- EPS past 5Y-6.50% ROI-38.80% 52W High-33.80% Beta0.78
Dividend %- Quick Ratio4.70 Sales past 5Y3.30% Gross Margin- 52W Low76.04% ATR0.26
Employees72 Current Ratio4.70 Sales Q/Q109.50% Oper. Margin- RSI (14)41.79 Volatility4.56% 5.15%
OptionableYes Debt/Eq0.46 EPS Q/Q17.70% Profit Margin- Rel Volume0.87 Prev Close5.21
ShortableYes LT Debt/Eq0.28 EarningsAug 04 AMC Payout- Avg Volume335.34K Price5.02
Recom2.50 SMA20-9.16% SMA50-0.98% SMA2000.01% Volume267,072 Change-3.71%
Aug-08-16Upgrade Cantor Fitzgerald Hold → Buy
Aug-05-16Reiterated Maxim Group Buy $12 → $9
Jul-07-16Initiated Maxim Group Buy $12
Apr-26-16Downgrade Leerink Partners Outperform → Mkt Perform
Apr-25-16Downgrade Piper Jaffray Overweight → Neutral
Apr-25-16Downgrade Cantor Fitzgerald Buy → Hold $9 → $5
Feb-03-16Reiterated Maxim Group Buy $13 → $12
Sep-16-15Initiated Cantor Fitzgerald Buy
Aug-14-15Initiated Leerink Partners Outperform
Apr-20-15Reiterated Maxim Group Buy $10 → $13
Jul-10-14Initiated Maxim Group Buy $10
Nov-13-13Reiterated Aegis Capital Buy $14 → $10
Oct-01-13Reiterated Aegis Capital Buy $14
Jul-16-13Initiated Cantor Fitzgerald Buy $10
Apr-01-13Reiterated Aegis Capital Buy $12 → $14
Dec-12-12Initiated Aegis Capital Buy $12
Aug-17-16 10:50AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:30AM  Blue Cross Blue Shield Illinois to Cover Trovera Liquid Biopsy Tests PR Newswire
Aug-16-16 12:47PM  ETFs with exposure to TrovaGene, Inc. : August 16, 2016
Aug-15-16 01:42PM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016
Aug-12-16 01:04PM  TROVAGENE, INC. Financials
Aug-09-16 11:01AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:34AM  Trovagene to Attend the 2016 Avondale Partners Healthcare 1-1 Conference PR Newswire
08:30AM  Trovera Urine Liquid Biopsy Test Provides EGFR Status to Inconclusive Tissue Biopsy: Case Report in Non-Small Cell Lung Cancer PR Newswire
Aug-08-16 07:29AM  TrovaGene upgraded by Cantor Fitzgerald
Aug-06-16 02:21PM  Edited Transcript of TROV earnings conference call or presentation 4-Aug-16 9:00pm GMT
Aug-05-16 08:33AM  TrovaGene (TROV) Loss Narrows Y/Y, Trovera Holds Promise -5.63%
Aug-04-16 07:37PM  Trovagene reports 2Q loss
05:12PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:15PM  Trovagene Reports Second Quarter 2016 Financial Results and Accomplishments PR Newswire
04:09PM  TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report
07:07AM  Q2 2016 Trovagene Inc Earnings Release - 4:00 pm ET
Aug-01-16 10:11AM  Will TrovaGene (TROV) Pull an Earnings Surprise in Q2?
Jul-26-16 04:32PM  TROVAGENE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obliga
08:45AM  Trovagene Schedules Release of Second Quarter 2016 Financial Results and Investor Conference Call PR Newswire
08:30AM  Diagnostic Performance of Urinary EGFR Testing in Lung Cancer Patients Published in Journal of Thoracic Oncology PR Newswire
Jul-13-16 06:05PM  TrovaGene Inks Partnership with USC Norris Cancer Center
Jul-12-16 10:49AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:30AM  Trovagene and USC Norris Comprehensive Cancer Center Collaborate to Standardize the Use of Trovera ctDNA Liquid Biopsy Tests in Patient Care PR Newswire
Jul-11-16 10:45AM  TROVAGENE, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
10:42AM  /C O R R E C T I O N -- Trovagene, Inc./ PR Newswire
Jul-07-16 04:31PM  TrovaGene Inks Partnership with University of Michigan +6.89%
Jul-06-16 10:51AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
09:58AM  Trovagene and University of Michigan Enter into Collaboration for Monitoring and Early Detection of Pancreatic Cancer PR Newswire
Jul-05-16 07:34PM  Trovagene to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference PR Newswire
Jun-24-16 05:48PM  ETFs with exposure to TrovaGene, Inc. : June 24, 2016 -5.21%
Jun-10-16 04:37AM  TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive (Revised) -12.30%
Jun-07-16 09:39AM  TrovaGene: Trovera Liquid Biopsy Urine Test Results Positive
Jun-06-16 11:16AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
11:00AM  ASCO Oral Presentation Demonstrates Trovagene's Liquid Biopsy Urine Test Detects EGFR T790M Mutations in Patients with Non-Small Cell Lung Cancer PR Newswire
Jun-03-16 03:45PM  ETFs with exposure to TrovaGene, Inc. : June 3, 2016
May-20-16 12:12PM  ETFs with exposure to TrovaGene, Inc. : May 20, 2016
May-19-16 02:50PM  TrovaGene, Inc. :TROV-US: Earnings Analysis: Q1, 2016 By the Numbers
08:48AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:05AM  Large Clinical Data Set in Lung Cancer Featuring Trovagene's Precision Cancer Monitoring® Platform Selected for Oral Presentation at the 2016 ASCO Annual Meeting PR Newswire
May-18-16 04:32PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers +7.30%
May-17-16 04:33PM  TROVAGENE, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders +5.12%
May-13-16 04:44PM  TROVAGENE, INC. Files SEC form 8-K, Other Events +9.86%
08:05AM  Large Clinical Study Demonstrates High Detection Rate and Ability to Monitor KRAS Mutations in Pancreatic Cancer Patients; Results Presented at 2016 AACR Pancreatic Cancer Meeting PR Newswire
May-11-16 08:16AM  TrovaGene (TROV) Q1 Loss Wider than Expected, Stock Gains
May-10-16 10:35PM  Edited Transcript of TROV earnings conference call or presentation 10-May-16 9:00pm GMT
06:09PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition
05:25PM  Trovagene reports 1Q loss
04:15PM  TROVAGENE, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
04:05PM  Trovagene Announces First Quarter 2016 Financial Results PR Newswire
07:07AM  Q1 2016 Trovagene Inc Earnings Release - 4:00 pm ET CCBN
May-05-16 01:13PM  Lifshitz & Miller Law Firm Announces Investigation of Apigee Corporation, Mentor Graphics Corp., PayPal Holdings Inc., Performance Sports Group, Ltd., PJT Partners, Inc., and Trovagene, Inc. PR Newswire +5.45%
May-03-16 08:15AM  Trovagene Schedules Release of First Quarter 2016 Financial Results and Investor Conference Call PR Newswire -6.02%
Apr-28-16 08:15AM  Trovagene to Present at the 41st Annual Deutsche Bank Healthcare Conference PR Newswire -6.31%
Apr-27-16 05:18PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online
09:16AM  What's in Store for TrovaGene (TROV) this Earnings Season? Zacks
Apr-25-16 04:48PM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits EDGAR Online -23.83%
08:05AM  Trovagene Appoints Bill Welch as Chief Executive Officer PR Newswire
Apr-15-16 02:02PM  Trovagene Gains 3% On Favorable Mention In Medical Journal
08:17AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:15AM  Patient Case Report Demonstrating the Ability of Trovagene's Precision Cancer Monitoring Platform to Determine Early Drug Response Published in Cancer Discovery PR Newswire
Apr-12-16 01:10PM  TrovaGene Inks Strategic Partnership with Stratose, Stock Up
Apr-11-16 10:01AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:15AM  Trovagene Enters Into Preferred Provider Agreement with Stratose PPO Network PR Newswire
Apr-08-16 02:25PM  Trovagene, Inc. (TROV): Bridger Management Reports 11% Stake and Goes Activist at Insider Monkey
Apr-07-16 06:58AM  TrovaGene To Present Clinical Data On Its Precision Cancer Monitoring Platform
06:09AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
06:05AM  Clinical Data Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the Molecular DX Europe Conference PR Newswire
Mar-30-16 01:41PM  SHAREHOLDER NOTICE: Goldberg Law PC Announces An Investigation of Claims against TrovaGene, Inc. And Advises Investors With Losses To Contact The Firm Business Wire -5.59%
11:26AM  Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Trovagene, Inc. - TROV PR Newswire
10:40AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of TrovaGene, Inc. Business Wire
09:48AM  Did a boardroom coup at Trovagene just create a buying opportunity?
Mar-29-16 06:41PM  IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces An Investigation of Claims against TrovaGene, Inc. And Advises Investors With Losses In Excess of $50,000 To Contact The Firm Business Wire
05:23PM  Harwood Feffer LLP Announces Investigation of Trovagene, Inc. PR Newswire
03:07PM  Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of TrovaGene, Inc. (TROV) PR Newswire
01:23PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Trovagene, Inc. - TROV Business Wire
12:20PM  TrovaGene Plunges on CEO and CFO Dismissal; Files Suit
09:42AM  TROVAGENE, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
08:48AM  Trovagene Interim CEO to Host Investor Conference Call at noodls
08:44AM  Trovagene Shareholder (TROV) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Trovagene, Inc.; Encourages Investors to Contact the Firm PR Newswire
08:36AM  Trovagene Interim CEO to Host Investor Conference Call PR Newswire
08:01AM  TrovaGene Down 40% Following Termination Of CEO, CFO
Mar-28-16 08:26PM  Biotech Trovagene Tumbles After Firing, Suing Its Top Executives
08:26PM  Biotech Trovagene Fires, Sues Its CEO, CFO; Shares Tumble at Bloomberg
07:48PM  Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause at noodls
07:30PM  Trovagene Terminates the Employment of CEO Antonius Schuh and CFO Stephen Zaniboni for Cause PR Newswire
Mar-24-16 08:18AM  Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016 at noodls
08:07AM  TROVAGENE, INC. Files SEC form 8-K, Other Events
08:05AM  Clinical Study Results Featuring Trovagene's Precision Cancer Monitoring Platform to be Presented at the AACR Annual Meeting 2016 PR Newswire
Mar-21-16 01:25PM  Why Healthcare Investors Should Forget about Drug Companies and Focus on Medical Device Companies Accesswire
Mar-11-16 12:40PM  Edited Transcript of TROV earnings conference call or presentation 10-Mar-16 10:00pm GMT -10.74%
09:20AM  TrovaGene (TROV) Falls on Wider-than-Expected Q4 Loss
Mar-10-16 11:40PM  /C O R R E C T I O N -- Trovagene, Inc./ PR Newswire -8.89%
06:17PM  Trovagene reports 4Q loss
05:03PM  TROVAGENE, INC. Files SEC form 8-K, Results of Operations and Financial Condition
04:14PM  TROVAGENE, INC. Files SEC form 10-K, Annual Report
07:07AM  Q4 2015 Trovagene Inc Earnings Release - 4:00 pm ET
Mar-08-16 08:15AM  Presentation at the Molecular Medicine Tri-Conference to Highlight Clinical Performance of Trovagene's Precision Cancer Monitoring Platform PR Newswire +5.85%
Mar-07-16 11:00AM  What's in Store for TrovaGene (TROV) in Q4 Earnings?
Mar-02-16 01:10PM  TrovaGene (TROV) Inks Deal with Multiplan; Shares Rally
Mar-01-16 08:17AM  TROVAGENE, INC. Files SEC form 8-K, Other Events +11.84%
Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It offers Precision Cancer Monitoring (PCM) platform, a cell-free molecular diagnostic platform that provides cancer monitoring by tracking and quantifying levels of cell-free DNA from either urine or blood samples, as well as intends to provide clinical information beyond the current standard of care. The company also provides assays for the BRAF, KRAS, and epidermal growth factor receptor oncogenes; and engages in developing mutation coverage for other cancers, such as lung cancer, as well as targeting clinically validated gene rearrangements, such as ALK, RET, and ROS. In addition, it offers laboratory developed tests for oncogene mutations to end users through a sales and marketing organization. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZANIBONI STEVEFormer CFOApr 21Option Exercise3.6575,639275,86696,968Apr 22 04:05 PM